• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Novo Integrated Sciences Inc.

    1/14/25 4:15:18 PM ET
    $NVOS
    Industrial Machinery/Components
    Industrials
    Get the next $NVOS alert in real time by email
    NT 10-Q 1 formnt10-q.htm

     

     

     

      UNITED STATES OMB APPROVAL
      SECURITIES AND EXCHANGE COMMISSION

    OMB Number: 3235-0058

      Washington, D.C. 20549 Expires: April 30, 2025
        Estimated average burden hours per response ... 2.50
      FORM 12b-25  
        001-40089
      NOTIFICATION OF LATE FILING SEC FILE NUMBER

     

    (Check one):

    ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR

    ☐ Form N-CSR

       
      For Period Ended: November 30, 2024
       
      ☐ Transition Report on Form 10-K
       
      ☐ Transition Report on Form 20-F
       
      ☐ Transition Report on Form 11-K
       
      ☐ Transition Report on Form 10-Q
       
      ☐ Transition Report on Form N-SAR
       
      For the Transition Period Ended:

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I — REGISTRANT INFORMATION

     

    Novo Integrated Sciences, Inc.

    Full Name of Registrant

     

    N/A

    Former Name if Applicable

     

    11120 NE 2nd Street, Suite 100

    Address of Principal Executive Office (Street and Number)

     

    Bellevue, WA 98004

    City, State and Zip Code

     

     

     

     
     

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

      (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
       
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
       
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III — NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    The filing by Novo Integrated Sciences, Inc. (the “Company”) of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended November 30, 2024 (the “Quarterly Report”) will be delayed due to the additional time that is required to obtain and compile certain information required to be included in the Quarterly Report, which delay could not be eliminated by the Company without unreasonable effort and expense. The Company expects to file the Quarter Report within the five-calendar day extension period.

     

    PART IV — OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

    Laura Anthony, Esq.   (561)   514-0936
    (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
      Yes ☒ No ☐
       
    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
      Yes ☐ No ☒ 
       
      If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     
     

     

    NOVO INTEGRATED SCIENCES, INC.

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: January 14, 2025 By: /s/ Robert Mattacchione
      Name: Robert Mattacchione
      Title: Chief Executive Officer

     

     

    Get the next $NVOS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NVOS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NVOS
    SEC Filings

    See more
    • SEC Form SEC STAFF ACTION filed by Novo Integrated Sciences Inc.

      SEC STAFF ACTION - Novo Integrated Sciences, Inc. (0001138978) (Filer)

      5/20/25 9:00:03 AM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences Inc. filed SEC Form 8-K: Leadership Update

      8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)

      5/6/25 4:30:35 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Novo Integrated Sciences, Inc. (0001138978) (Filer)

      5/2/25 4:13:03 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials

    $NVOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer David Christopher Mehlin

      4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)

      9/12/24 6:05:09 AM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by David Christopher Mehlin

      4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)

      6/2/23 4:05:37 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by Novo Integrated Sciences Inc.

      4 - Novo Integrated Sciences, Inc. (0001138978) (Issuer)

      8/10/22 1:01:17 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials

    $NVOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results

      Novo Integrated Sciences, Inc. (OTC:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, today reported its financial results for the fiscal year ended August 31, 2024. Robert Mattacchione, the Company's CEO and Board Chairman, stated, "The Company remains committed to the commercialization of its proprietary product offerings and the expansion and delivery of its essential services and solutions to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and

      12/18/24 4:05:00 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results

      Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation, today reported its financial results for the third fiscal quarter ended May 31, 2024. Robert Mattacchione, Novo's CEO and Board Chairman, stated, "The Company's fiscal year 2024 third quarter emphasized maximizing operational efficiencies for all business units. The Company continues to work with certain prospective financial partners to close previously announced non-traditional financing opportunities to raise foundation

      7/19/24 5:00:00 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program

      Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today that it has received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit ("SBLC"). The initial disbursement represents the first payment as per the arrangement creating a release of lien resulting in the subsequent final advance to the Company. With this initial disbursement the Company expects final distribution to follow on or before August 2. As previously reported, the Company entered into an application for the monetizing program whereby the Company is projected to receive gross funding proceeds of approximately $78 million under the SBLC monetizatio

      7/18/24 4:05:00 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials

    $NVOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Novo Integrated Sciences Inc. (Amendment)

      SC 13G/A - Novo Integrated Sciences, Inc. (0001138978) (Subject)

      2/6/24 12:00:24 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G/A filed by Novo Integrated Sciences Inc. (Amendment)

      SC 13G/A - Novo Integrated Sciences, Inc. (0001138978) (Subject)

      2/10/23 3:45:24 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G filed by Novo Integrated Sciences Inc.

      SC 13G - Novo Integrated Sciences, Inc. (0001138978) (Subject)

      2/8/22 4:28:22 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials

    $NVOS
    Leadership Updates

    Live Leadership Updates

    See more
    • Novo Integrated Sciences Appoints New President

      Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announces today Mr. Robert Oliva has been appointed as the Company's new President. Mr. Oliva succeeds Mr. Christopher David, who remains as the Company's Chief Operating Officer and as a member of the Company's Board of Directors. Mr. Oliva has over 35 years of ownership and proven business development with expertise in manufacturing related operations. Mr. Oliva is expected to advance the Company's product-related operational efficiency while managing aggressive, yet sustainable growth and improving margins. Robert Mattacchione, the Company's CEO and Board Chairman, stated, "The addition of Mr. Oliva comes at a tim

      2/16/24 2:00:00 PM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences Appoints Dr. Indrajit (Indra) Sinha Ph.D. as Chief Science Officer

      Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announces that Dr. Indrajit "Indra" Sinha, Ph.D. has been appointed as Novo's Chief Science Officer, effective June 24, 2021. Dr. Sinha brings over 25 years of experience in various areas of cross-disciplinary translational research, drug development, biotechnology, technology transfer, and biopharmaceutical compliance. His work has been extensively published in highly reputed peer reviewed journals. Through his passion for utilizing under-appreciated technologies and applying them in innovative ways to achieve previously unattainable outcomes, he has created various intellectual property and patents. Robert Mattacchio

      7/7/21 8:00:00 AM ET
      $NVOS
      Industrial Machinery/Components
      Industrials

    $NVOS
    Financials

    Live finance-specific insights

    See more
    • Novo Integrated Sciences Completes Acquisition of Clinical Consultants International LLC

      Dr. Joseph M. Chalil, MD, MBA, FACHE Appointed Chief Medical Officer and the New President of Novomerica Health Group Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, today announced the Company has completed the acquisition of Clinical Consultants International LLC ("CCI"), a global consulting firm, based in Boca Raton, Florida, specializing in providing value-added services for the pharmaceutical, biotech, healthcare management, hospital management, medical marketing and strategic planning, health policy, and medic

      4/7/22 8:00:00 AM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences Acquires Majority Stake in Terragenx and Intellectual Property for FDA and Health Canada Approved Water-Soluble Iodine Micro-Nutrient

      Iodine, an essential nutrient, when in aerosolized aqueous form can be safely ingested to kill bacteria and deactivate various viruses Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo"), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation, announced today it has acquired 91% of Terragenx and the intellectual property portfolio for the unique formulation and manufacturing capability to produce a water-soluble iodine micro-nutrient that is FDA and Health Canada approved for over-the-counter and e-commerce distribution (the "Iodine IP and Patents"). Iodine is a naturally oc

      11/30/21 8:00:00 AM ET
      $NVOS
      Industrial Machinery/Components
      Industrials
    • Novo Integrated Sciences and Novo Healthnet Limited Complete Acquisition of Acenzia

      Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the "Company" or "Novo") announced today Novo Healthnet Limited, a wholly owned subsidiary of the Company ("NHL"), completed the acquisition of Acenzia Inc., a Windsor Canada based company that provides nutraceutical health solutions through advanced bio-science research and development, proprietary manufacturing, and personalized diagnostics. The all-share transaction, which closed on June 24, 2021, is valued at $14,884,039, or $3.91 per share, and is subject to purchase price adjustment within 90 days of the closing date pending completion of an audit and working capital requirement provisions. Robert Mattacchione, Novo's Chairman and CEO, st

      6/29/21 8:00:00 AM ET
      $NVOS
      Industrial Machinery/Components
      Industrials